ABSTRACT
INTRODUCTION
Immunotherapy for cancer treatment has been extensively studied not only to improve the quantity of the immune cell mediators but also in quality (such as function) of these mediators to maximize the efficiency of immunotherapy 1, 2 . It cannot be ignored that immune cell therapy plays a very important role in cancer treatment 3, 4 . In general, the purpose of cancer treatments is to reduce tumor size and ultimately eliminate cancer cells 5 ; when the tumor is not detectable anymore at the cellular level, this is evidence for successful therapy 6 . It is also the goal of immune cell therapy to demonstrate full and convincing ability to destroying the body's abnormal cells, including cancer cells 7 . Normal cells of the body accumulate mutations that cannot be recovered. In fact, some cancer cells arise from normal cells have a breakdown in the mechanism of self-control of cell growth, which can gradually lead to formation of tumors 8 . There is a disruption of the molecular balance between oncogenes and tumor-suppressor genes 9 . When this cell balance is disrupted, this can lead to an inbalance between cancer cells and immune cells 10 . The latter balance is considered the last and very important barrier that the body makes. If this barrier is properly maintained, cancer does not have a chance to progress and should degrade quickly and easily 11 . However, when this barrier becomes extremely fragile, cancer cells can pass the check-points, thereby allowing mutation cascades to take place, which can trigger uncontrolled proliferation 12 . Finally, the quantity of cancer cells becomes overwhelming to immune cells 13 . It is also because of the accumulation of many mutations that cancer cells easily transform their own characteristics, including dealing with the immune system 14 . When an inadequate amount of immune cells exists, cancer cells just keep evading from immune surveillance 15 until the quantity of cancer cells increases; these cells now can tolerate the immune system that was intended to engage or attack them 16 . However, there are still many opportunities to cure cancer. There have been many improvements in routine treatments, such as surgery, chemotherapy and radiotherapy for cancer-to increase the ability to eliminate tumor cells 17 . However, such conventional treatments are non-targeted treatments. For example, surgery is difficult to detect micro-tumors, while chemotherapy and radiation kill the proliferating cells, including normal cells of the body 18 . As a result, patients suffer from harmful side effects and disease easily recurs. As one of the novel approaches to find ways to destroy cancer cells effectively and overcome the limitations of routine therapies, immunotherapy has been studied extensively and has become prominent, achieving many encouraging results 19 . As mentioned above, the amount of immune cells capable of identifying and destroying cancer cells needs to be ensured and maintained 20 . This is difficult to achieve in patients with advanced disease or when they have undergone conventional therapy since as the disease progresses, the quantity of cancer cells completely overwhelms the immune cells 21 . In the latter situation, there are two unexpected outcomes which can occur: severely affected immune cells can't be recovered both in number and function, and cancer cells can survive after treatment (even acquiring strong resistance to the conventional methods) 22 . This also explains why there are many promising results. In general, though, the effectiveness of immunotherapy has not been as expected 23 . Part of this is due to the fact that the cells responsible for tissue and organ regeneration (stem cells) are negatively affected by chemotherapy and radiation, and the immune system is severely impaired 24 . A more appropriate approach towards cancer treatment is a combination of therapies that can combine widely used methods and/or incorporate novel, targeted ones 25 . The combination helps promote the advantages of each method as well as limit their deficiencies. In particular, the combination helps reduce the dose of chemotherapy and/or radiation therapy that is administered in patients 26 . The immediate benefit is to limit or prevent unwanted side effects. In the types of immune cells studied, two candidates emerged from both arms of the immune system: dendritic cells (DCs) from innate immunity 27 and cytokine-induced killer cells (CIK cells) from adaptive immunity 28 . Dendritic cells (DCs) are the most professional antigen-presenting cells (APC) 29 . APCs process protein into peptide fragments, which incorporate with major histocompatibility complex (MHC) and are presented to T cells 30 . A simultaneous secretion of co-stimulating factors are necessary for the recognition of antigen via the T-cell receptor (TCR) 31 . DCs are capable of activating both naive and memory T cells, while macrophages only present antigens to specific T cells, and B cells present antigens to helper T cells 32 . DCs have been considered to be the center of the immune system because they are capable of stimulating humoral and cellular immune responses 33 . In other words, both innate immunity (via activation of natural killer cells (NK cells), macrophages, and mast cells) and adaptive immunity are in play. DCs are a heterogeneous population of cells, possessing different markers and playing different roles in the immune response 34 . DCs are scattered throughout the covered surfaces of the body in the immature phenotype, ready to arrest foreign pathogens 35 . After capturing antigen, DCs perform the processing function and present the antigen to the cell surface, and they move to the T cell-rich region to present the antigen 36 . In vitro, DCs have been isolated and differentiated from bone marrow CD34+ cells, peripheral blood, and umbilical cord blood mononuclear CD14+ cells 37 . Hematopoietic stem cells have been cultured under the supplementation of stimulating factors, such as GM-CSF, IL-4 and Tumor necrosis factor-α (TNF-α), to differentiate into DCs 38 . After the antigen is processed, DCs rapidly move into secondary lymph nodes, presenting antigens to naive T cells to stimulate immune cells, including CD4+ T cells (TH1) and CD8+ T cells 39 , to activate memory B cells and inactive B cells, NK and NKT cells 40 . Cytokine-induced killer (CIK) cells are a type of cytotoxic T-cells with the phenotype of both T lymphocytes and NK cells 41 . In 1990, Schmidt-Wolf and colleagues discovered that CIK cells, which exist in the form of motile cell populations, when they differentiated peripheral blood mononuclear cells with cytokines, such as interferon-gamma (IFN-γ), anti-CD3 mAb and interleukin-2 (IL-2) 42 . CIK cells are a heterogeneous cell population that is highly toxic to tumor cells both in vitro and in vivo, without being limited by MHC and which cause low graft reaction 43 . Their phenotypes include: CD56+CD3+, CD56+CD3-and CD56-CD3+ 44 . CIK cell toxicity is closely related to increased expression of CD56+ and CD3+ markers 45 . CIK cells are capable of independent cytotoxicity and rapid growth in culture, making it easier to infuse initially than using T cells 46 . In co-culture, antigen-induced DCs is responsible for directing CIK cells to directly lyse tumor cells by secreting cytokines, such as TNF-α, IL-2, and IL-12 47 . These two types of cells receive a lot of attention because they can be easily obtained from differentiating mononuclear cells in cord blood 48 , which could be of great application significance when we can easily isolate, proliferate and select them, then infuse functional cells back into patients with the goal of killing cancer cells 49 . There are many studies that demonstrate the ability of DCs and CIK cells in vitro 50 51 . However, the treatment effect is low if only DCs were infused into patients when the immune system no longer has enough functional cells to destroy cancer, or if only CIK cells were infused (without previous priming). Thus, the time to recognize cancer cells is delayed, which results in the uncontrollable incident when tumor mass becomes significant. The combination of DCs and CIK cells helps to limit the mentioned disadvantages, and DCs can present cancer cell antigens to CIK cells by hundred-fold increase 52 . After being administered into the patient's body, these cells help find and carry out the mechanism of poisoning of cancer cells without harming normal cells. The goal of this study is to understand whether priming from DCs can help CIK cells to express their toxic function, and kill the cancer cells. The results from this study are clear evidence that the adequate combination helps the immune system to effectively identify and destroy cancer cells, and thus DC-CIK cell mixture is a potential platform choice for cancer immunotherapy.
MATERIALS AND METHODS

Human materials
Cord blood samples were collected from three healthy pregnant women at the Van Hanh Hospital following consent from donors. The collection procedure and usage of these blood samples were approved by the hospital ethical committee. Breast cancer cells (VNBRCA) and human fibroblasts (hF) were provided from the biological bank of Stem Cell Institute (VNUHCM University of Science). These cells were cultured in DMEM/F12 medium containing 10% fetal bovine serum (FBS) and 1x Antibiotic-Antimycotic (Gibco, Carlsbad, CA).
Method to produce cancer antigen
Confluent cancer cells were trypsinized and pelleted, then suspended in 1ml of PBS. Membrane breaking was conducted by quick freeze-thaw method: -196 0 C in liquid nitrogen, 2 minutes → 37 0 C, 2 minutes 30 seconds → vortex 30 seconds; this process was replicated 5 times. Samples were centrifuged at 13000 rpm, 5 minutes, 4 0 C. The suspension was collected, and the antigen concentration was quantified by Bradford method.
Bradford method
To determine the amount of protein in the sample, a known standard protein curve was made that showed the correlation between concentration and absorption value at 595 nm (OD595). A common standard protein solution is bovine serum albumin (BSA). After adding the dye to the protein solution, the color will appear within 2 minutes and last up to 1 hour. The optical density measurement was performed with a spectrophotometer (DTX 880, Beckman Coulter). Standard BSA protein (0.1mg/ml) was made. Protein (antigen) samples were tested by diluting with distilled water (diluted 100 times). Bradford solution was diluted 2.5-fold with distilled water. A standard BSA curve was made: 0, 20, and 40-100 μl of standard BSA solution (0.1 mg/ml) was aliquoted into each well and distilled water added to 100 μl. Antigen samples (100 μl each) were added into the other wells then 100 μl of Bradford solution was added to each well. The blank well contained 200 μl of distilled water. The wells were shaken for 5 minutes at room temperature. Optical density (OD) at 595 nm wavelength was measured. From the measurement results, a standard protein curve was created for the relation between protein concentration and OD595 values. The value of the antigen concentration to be measured was extrapolated.
Isolate umbilical cord blood mononuclear cells
Based on the difference in density of blood cells, granulocytes and erythrocytes were separated from mononuclear cells. Granulocytes and erythrocytes have a higher density at osmotic pressure of Ficoll, and are deposited through the Ficoll layer during centrifugation. Mononuclear cells with a lower density are in the middle of the plasma-Ficoll layer. Mononuclear cells can be easily collected, then washed to remove platelets, Ficoll and plasma. The following is the step-wise procedure for collecting mononuclear cells: Aliquot blood from blood collection bags into 50 ml centrifuge tube. Dilute blood with sterile PBS at a ratio of 1: 1. Add 15 ml Ficoll straight to the bottom of a 50-ml centrifuge tube. Add 30 ml diluted blood on the Ficoll layer. Avoid disturbance between Ficoll and blood, and create clear layer. Centrifuge at a speed of 400 g, 30 minutes, 25 0 C. Remove the above plasma layer without affecting the interface between the plasma-Ficoll. Transfer the mononuclear cells at the plasma-Ficoll interface into another centrifuge tube, wash with sterile PBS (mixed at a ratio of 1: 1), and centrifuge at 800 g, 10 minutes. Remove the supernatant, collect cell pellet, and suspend with 5 ml red blood cell lysis buffer for 5 minutes at room temperature. Add PBS to 20 ml, centrifuge at a speed of 300 g, 6 minutes. Repeat once. Suspend cell pellet with 5 ml of basic culture medium and transfer to sterile culture flask. Incubate in a 37 0 C, 5% CO2 incubator. After 2 hours, transfer the cell suspension to another culture flask and continue incubating at 37 0 C, 5% CO2 in the incubator. Perform 2 more times to get MNCs, and differentiate into DCs. For the last step, take the cell suspension to differentiate to CIK cells. The determination of MNC cell count was done by Trypan blue staining and marker expression of MNC sample was tested at the end of the experiment.
Differentiation of cord blood cord mononuclear cells into DC and CIK cells
Differentiation of DCs
Mononuclear blood cells could be obtained from peripheral blood or umbilical cord blood. In this study, DC were induced to mature from cord blood mononuclear cells by a 10-day procedure. Phase 1, day D1: obtained from the attached mononuclear cells in culture flask. Induction of mononuclear cells by CM1 medium (containing 40 ng/ml IL-4 and 50 ng/ml GM-CSF). Refresh the culture medium every 3 days. Phase 2, day D7: Determine cell density and conduct maturation of immature DC (iDCs) with antigen (Ag) lysates with concentration of 50 μg/ml medium. Phase 3, day D10: mature DCs were obtained. DC cell density was evaluated to determine the amount of cells needed to perform DC-CIK co-culture. Phase 4, day D14: DC samples cultured in CM1 medium were collected and used in MTT assay (group of DC+CIK individual cell experiments). Evaluation of cell growth was done by determining the number of cells obtained on day D10 and day D14 by Trypan blue staining.
Differentiation of CIK cells
In this study, we isolated MNCs on day D0, then cultured them, and induced and differentiated them into CIK cells for 14 days the following procedure: MNCs were cultured in RPMI-1640, 10% FBS, and 1% antibiotic. On day D0, MNCs were induced with IFN-γ 1000 U/ml, and on D1 they were induced with 50 ng/ml anti-CD3 Ab and 1000 U/ml IL-2. The medium was refreshed with 1000 U/ml IL-2 every 3 days.
DC-CIK Co-culture
In co-culture, DCs and CIKs can directly or indirectly interact using physical or chemical barriers (e.g. EDTA in the culture medium). In this experiment, DC-CIK co-culture was in RPMI-1640, supplemented with IL-2 (1000 U/ml). The ratio used in this experiment was DC:CIK = 1:10, in which DCs were previously induced to mature before co-culture.
On D10, DCs and CIK cells were collected from culture, and cell density was determined with Trypan blue staining. DC-CIK co-culture was done at a ratio of 1:10 in RPMI-1640 medium, supplemented with IL-2 (1,000 U/ml). Proliferation of the mixture was evaluated after 4 days (D10-D14). The typical phenotypic expression of CIK cells (e.g. for Granzyme B and CD3+CD56+ markers) was evaluated in the coculture by flow cytometry.
Evaluation of CIK gene expression after 4 days of co-culture
At day D14, cells in the culture plates were collected.
Acquisition of total RNA using easy-BLUE T M
The protocol was as follows:
Collect 5x10 5 cells in each group to harvest total RNA. Add 500 μl easy-BLUE T M , and vigorously vortex to completely dissolve cell pellet. Add 200 μl Chloroform and vigorously vortex. Centrifuge 13,000 rpm for 10 minutes. Gently aspirate the supernatant layer into a new 1.5 mL centrifuge tube, avoiding disturbance of the middle protein layer. Add isopropanol to the tube at the same volume. Incubate for 10 minutes at 4 0 C and then centrifuge at 13,000 rpm for 10 minutes. Discard the supernatant and dry the pellet. Add 1 ml of 70% Ethanol, invert the tube few times, and centrifuge at 10,000 rpm for 5 minutes. Discard the supernatant and dry the pellet. Then, dissolve RNA pellet in 20-30 μl DEPC water. Finally, use 6 μl RNA solution to measure OD (determination of total RNA concentration) and perform electrophoresis to determine RNA quality after separation. hF cell RNA was isolated for the control group.
RT-PCR
The brightness of RT-PCR products on the electrophoresis was analyzed by ImageJ software (NIH, USA) and GraphPad Prism (GraphPad Software, San Diego, CA). 
RESULTS
Protein concentration determination by Bradford method
The standard protein curve is a linear line between protein concentration and OD value measured at a wavelength of λ 595nm (OD595). Protein concentration value can be easily determined by the equation: y = 1.8479x + 0.5878, where x is the protein concentration (mg/ml), and y is the value at OD595. Based on the linear equation, we deduced that the antigen concentration obtained after VNBC cancer cell lysis. Antigen concentration (from the results) was 1.97 mg/ml.
Differentiation of DCs, CIK cells and DC-CIK co-culture
Differentiation of DCs
After 24 hours of primary culture, mononuclear cells were differentiated into immature DCs in CM1 medium supplemented with 50 ng/ml GM-CSF and 40 ng/ml IL -4. After 4 days, when observing the cells culture under a microscope, a group of dendritic cells which attached on the surface of flask appeared; another group of cells attached but did not yet grow branched projections. The remaining component of the culture was floating cells (Figure 3A) . After 7 days, immature DC candidate cells were induced to mature in CM1 medium supplemented with VNBRCA antigen at a concentration of 50 μg/ml ( Figure 3B) . After 3 days of antigen exposure (D10), DCs had a marked morphological change, which is a sign of maturity. The group of half-adhered and suspended cells was much higher than in the previous period (data not shown) and DCs have fewer dendrites. The change of immature and mature DC morphology partly aids in seeing the effects of antigens added to the culture medium ( Figure 3C and D) .
Differentiation of CIK cells
MNCs obtained in the last transfer were used to induce CIK with primary culture medium supplemented with IFN-γ (1000 U/ml). After 24 hours, 50 ng/ml anti-CD3 Ab and 1000 U/ml IL-2 were added to the CIK culture medium. On D14, a homogeneous CIK population was obtained; the cells had a rounded morphology and showed strong proliferative capability.
DC-CIK cell co-culture
On D10, a co-culture of DC and CIK cells was initiated, at a 1:10 ratio (DC:CIK) in RPMI-1640 medium supplemented with 1000 U/ml IL-2.
The proliferation of DCs, CIK cells, and DC-CIK during culture
From D10-D14, the density of the cell populations differentiated from cord blood mononuclear cells (DCs, CIK cells and DC-CIK cells) was checked (Figure 6 ).
The rate of cell proliferation on day D14 compared with day D10 is determined by the formula: Bovine serum albumin (BSA) standard protein curve was made that showed the correlation between concentration and absorption value at 595 nm (OD595). Data shown as mean ± SD of triplicate wells. Theoptical density measurement was performed with a spectrophotometer. Confluent cancer cells were used to produce protein mixture by quick freeze-thaw method. The value of the antigen concentration to be measured was extrapolated.
The rate of cell proliferation after 4 days of culture (D10-D14) of the groups differed significantly (p<0.05). In particular, CIK cells had the fastest growth rate (average of 133.88%), DC-CIK co-culture had slower growth rate (average 33.7%), and DCs no long proliferate (growth rate<0). The results of growth rate reflect the physiological state of the cell. In culture on D14, DCs had been induced to mature and were dying, CIK cells had a rapid growth rate during the culture period of 14-21 days. The proliferation in the DC-CIK group reflects the effectiveness of the DC-CIK co-culture. After exposure time (4 days 
Gene expression
RNA was harvested with high purity and without rupture.
In the three samples of gene expression analysis, the results showed that the DC-CIK co-culture stimulated a strong expression of IFN-γ in comparison with the CIK alone (p <0.0001). There were no differences be- After co-culture period, it is easy to see that the cell mixture has strong proliferation capacity which occupies the entire culture flask surface into many cell layers (the spherical cells cover the cell layer below), which shows that there is an interaction between the two cell types keeps them dividing. tween TNF-α and IL-2 gene expression between those groups.
Evaluation of marker expression in DC-CIK co-culture and CIK cell populations
The expression of intracellular marker (Granzyme B) and surface marker (CD3 + CD56 + ) among the groups differed significantly (Figure 9) . For Granzyme B, MNCs showed the lowest expression (18.74% ± 10.92), while DC-CIK co-culture showed the strongest (70.47% ± 1.53, 4 times higher than MNCs). The lowest expression of Granzyme B was observed for CIK cells (42.67% ± 7.78, 2.28 times greater than MNCs). For CD3+CD56+, the co-culture showed the most expression (13.27% ± 2.73), which is 13 times higher than that for MNCs (1.02% ± 0.11). Note that CIK cells expressed lower (6.82% ± 2.42, nearly 6.67 times that of MNCs). The results showed that coculture expressed the strongest expression, which is better than CIK group. This proves that co-culture facilitates DCs and CIK cells to interact with each other, increasing the CIK cell toxicity after exposure to DCs induced with antigen. Therefore, the analysis results of flow cytometry prove that DC-CIK co-culture has the effect of increasing the ability of CIK to induce tumor cell cytoxicity.
Evaluation of the ability to cause VNBRCA cell death of DC-CIK co-culture
Experiments were conducted on two cell lines (VN-BRCA and hF) with 3 cell effector cell groups, namely the co-culture (DC-CIK), individual (DC+CIK), and CIK, which assessed the ability to target cancer cells through the priming of DCs in DC-CIK and DC+CIK groups, compared to the CIK group. The time of contact with target cells in 48 hours (for sample 1 and sample 2) was evaluated, as well at 72 hours (for samples 3 and 4). The results of VNBRCA and hF cytotoxic assessment are expressed by the ratio of dead target cells when contacting with effector cells. After 48 hours of exposure with effector cells, in sample 1, effector cells do not affect fibroblasts (hF cells) but cause cell death on VNBRCA breast cancer cells (Figure 10) . In terms of VNBRCA cell death, cells in the individual culture group (DC+CIK) gave the best removal efficiency (41.21% ± 1.02), which was 3.73 times more than the DC-CIK group (11.06% ± 0.54), while the CIK group was lowest (20.72% ± 1.11), and was 1.83 times greater than the DC-CIK group (Figure 10) . In sample 2, effector cells did not affect fibroblasts but caused cell death on VNBRCA breast cancer cells (Figure 11) .
In considering VNBRCA cell death, cells in DC+CIK and CIK groups gave better killing efficiency than the co-culture group (6.59 % ± 0.22). The rate of cell death induced on VNBRCA cells did not differ between the 2 groups of effectors: DC+CIK cells (23.63% ± 0.94) and CIK cells (24.50% ± 1.78), (p = 0.0603 > 0.05, Figure 11) . Thus, after 48 hours, effector cells do not have toxic effects on hF cells but are capable of lethality on VNBRCA cells, show since the group of effector DC+CIK cells showed toxic effects more significantly than the 2 groups of CIK and DC-CIK. After 72-hour exposure, in sample 3, the effector cells of DC+CIK and CIK group caused toxic effects on both hF and VNBRCA target cells (Figure 12) . On VNBRCA cells, the effector cells of DC+CIK cells had the highest cell death effect (91.09% ± 4.17), which was 1.6 times higher than the DC-CIK group (57.24% ± 3.2). CIK cells do not make deadly effects on VNBRCA cells (Figure 12) . In sample 4, DC+CIK effector cells caused toxicity on both target cell lines, while DC-CIK cells had the most effective VNBRCA cytotoxicity.
For hF cells, the groups of effector DC-CIK and CIK cells did not kill target cells, but DC+CIK cells had toxic effects on cell death at the rate of 31.71% ± 2.65. For VNBRCA cells, the lowest rate of cell death was in the CIK group (20.58% ± 3.24), DC+CIK group had the highest cell death rate (53% ± 6.01, 2.58 times more than CIK), and the DC-CIK group had the lowest toxic effect (25.01% ± 1.94, 1.22 times higher than CIK cells) (Figure 13 ). After 72 hours, DC+CIK cell group had the highest VNBRCA cytotoxic effect but also killed hF cells. Therefore, DC-CIK co-culture induced optimal cytotoxic effects after 72 hours of exposure to target cells. In summary, for the hF cells, cells of DC+CIK and CIK groups had the effect of causing cell death after 72-hour exposure, in which the cell death rate of DC+CIK group was high (38.24% ± 7.69 on average). Meanwhile, the DC-CIK group does not cause hF target cell death after both time points. For VNBRCA cells, all 3 groups of the effector cells have a lethal effect on cancer cells, in which DC+CIK group gave the highest effect. The lethality of the DC-CIK group increased after 72-hour exposure with the target cell. Therefore, DC-CIK co-culture has the most specific ability to eliminate VNBRCA breast cancer cells with only causing lethal effects on cancer cells yet without causing toxicity on fibroblasts (hF). The optimal toxicity of this group on VNBRCA occurs after 72 hours. 
DISCUSSION
Our body is capable of stimulating immune responses to remove abnormal cells (cancer cells) 53 . The use of the immune system to eliminate cancer cells in the body is well known as immunotherapy for cancer treatment 54 . One of the main methods used is immune cell therapy 55 . Immune cells have been cultured in vitro in which they are induced to strongly identify tumor cells before being infused into cancer patients 56 . In vitro cultivation of DCs and Cytokineinduced Killer cells (CIK cells) -a special phenotype of T lymphocyte populations-for cancer treatment has gained increasing research interests 57 . Mononuclear cells were collected and cultured in primary culture supplemented with 10% serum (FBS) to enhance selection of cells capable of adhering to the surface of the flask; this helps to maximize the cells with good adhesion, creating a good cell source for DC differentiation 58 . In addition, FBS supplementation is also convenient for transferring the cell suspension afterwards and removing red blood cells about 2-3 hours later. According to Steinman and Cohn (1973) , the ability of mononuclear cell adhesion decreases with time in the primary medium, so that the transferring creates space for the best mononuclear cell adhesion 59 . It is very important to remove red blood cells from the first stage of isolation 60 . If it has been done without caution, mononuclear cell samples have an abundance of both platelets and erythrocytes, affecting the effectiveness of the subsequent lysis process. This makes it difficult to determine the number of cells or containment of noise signal via interference marker analysis. Mononuclear cell population with the best adhesion capacity obtained during the first transfer was used as cell source for DCs differentiation 61 . The cell population in the final transfer was used to induce into CIK cells because these cells are non-adherent cells. DCs are one of the professional antigen presenting cells (APC) of the immune system 62 . DCs are able of capturing and presenting foreign antigens to T lymphocytes, thereby activating naive T cells into antigenspecific cytotoxic T cells 63 . On the other hand, activated T-cells secrete cytokines to stimulate the proliferation of DCs 64 . The co-culture of T-cells and antigen-primed DCs will stimulate the proliferation and toxicity of T cells. In vitro, CD14+ mononuclear cells can be induced and differentiated into DC with the presence of GM-CSF, IL-4, and TNF-α (tumor necrosis factor-α) 65 . GM-CSF is believed to ensure the existence and differentiation of monocytes in vitro, while IL-4 has been shown to inhibit the differentiation into macrophages 66 . TNF-α also helps to produce high levels of IL-12p70, thereby enhancing the ability to activate TH1 and CTLs 67 . In studies using DC in cancer therapy, replacing necrosis factor TNF-α by tumor antigen is increasingly concerning but markedly effective, especially in in vivo and clinical trials 68 . Quick Freeze-Thaw is a common physical method normally used for mammal cell lysis 69 . This method relies on mechanical impact directly on cell membrane by forming ice crystals during the freezing causing tearing, breaking cell membrane 70 . Cells will be cleaved into smaller peptides 71 . Cancer antigens are biological agents induced dendritic cell maturity as a physiological condition in the body 72 . The use of antigens derived from tumor cell lysis to induce DC maturation is necessary to provide strong antitumor effect in both in vitro and in vivo 73 . After being exposed to antigens, DCs reduce adhesion and are able to migrate to lymph nodes due to secretion of cytokines, such as TNF-α, IL-1 β 74 . In particular, TNF-α is the stimulus for differentiating immature DCs into mature DCs 75 . The change of DC cell morphology pre-and post-antigen exposure (or immaturity and maturity) is clearly demonstrated by observations on D7, D10 and D14 ( Figure 3B , C, and D). Immature DCs have distinctly long dendrites and better adhesion than mature DCs 76 . Mononuclear cells isolated from peripheral blood may be induced into CIK cells by IFN-γ, anti-CD3 antibody, and IL-2 77 . CIK cells have T lymphocytes and natural killer (NK) cell characteristics, and contain heterogeneous phenotypic features (e.g. CD3-CD56+, CD3+CD56-, and CD3+CD56+) 78 . CIK cells have pre-eminent traits, such as rapid proliferation, toxicity to cancer cells regardless of HLA and low rejection ability 79 . CIK cells are capable of rapid growth during the 2-3 week culture period, and CIK cells can grow up to a few hundred fold 80 . Control of IFN-γ induction before supplementation with IL-2 and anti-CD3 antibody is crucial in creating cytotoxicity 81 . Specifically, IFN-γ activates monocytes to provide an important signal in CD56+ T-cell proliferation 82 . The addition of IL-2 and anti-CD3 then mainly provide mitotic signals 83 . CIK is a round-shape, floating cell population, not adhering in culture ( Figure 4B, C and D) .
In our body, cell populations cannot function independently, but have an interaction with other cell populations to coexist 84 . Cell co-culture is one of the methods to determine the interplay between populations, which can stimulate or inhibit each other 85 . Co-culturing DCs and T cells to stimulate the body's immune response to pathogens as well as cancer cells has yielded positive results 86 . However, the method also has certain limitations such as weak T-cell vitality, low quantity of T-cells isolated from patients, and cultured T-cell characteristic alteration. All of these factors increase in the risk of T-cell rejection out of the patient's body 87 . Bearing the characteristics of CD3+ T lymphocytes, CIK cells are able to identify the antigen presented on DCs 88 . Co-culture of DCs and CIK cells is capable of increasing the expression of CIK-specific characteristics and CIK toxicity on cancer cells 89 . The ratio of DC-CIK co-culture is as diverse as 1: 3, 1: 5, 1:10, and 1:20, according to previous studies 90 91 . The ratio used in this experiment was DC:CIK = 1:10. After exposure time (4 days), DCs and CIK cells interacted with each other, and DCs interacted with and secreted cytokines that stimulate CIK cells to proliferate (Figure 6 ). In addition, DC-CIK co-culture also stimulated strong expression of IFN-γ ( Figure 8B) . The analysis results of flow cytometry demonstrate that DC-CIK co-culture highly express Granzyme B and CD3+CD56+ markers (Figure 9) . Specifically, DC-CIK co-culture has the most specific lethal effects on cancer cells after 72 hours.
CONCLUSION
The combination of DCs with CIK cells-with a function to determine the target cancer cells-is a potential combined strategy with high efficiency and safety compared to traditional therapies, such as chemotherapy and radiotherapy, which cause systemic immunodeficiency.
